Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a …
Y Takaoka, T Suzuki, D Yoneoka… - Cochrane Database …, 2021 - cochranelibrary.com
Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Cardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor
agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new …
agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new …
Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome
W He, J Wei, X Liu, Z Zhang, R Huang, Z Jiang - Scientific Reports, 2024 - nature.com
Pathological cardiac hypertrophy is an important cause of heart failure (HF). Recent studies
reveal that glucagon-like peptide-1 receptor (GLP1R) agonists can improve mortality and left …
reveal that glucagon-like peptide-1 receptor (GLP1R) agonists can improve mortality and left …
Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice
LM Pérez-Belmonte, J Sanz-Cánovas… - Frontiers in …, 2022 - frontiersin.org
Background The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …
Biomarker changes associated with both dulaglutide and cardiovascular events in the REWIND randomized controlled trial: A nested case-control post hoc analysis
HC Gerstein, SF Lee, G Paré, MA Bethel… - Diabetes …, 2023 - Am Diabetes Assoc
OBJECTIVE The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the
Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This …
Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This …
Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials
SY Wong, ARYB Lee, AHJ Sia, YJ Wo, YH Teo… - … Drugs and Therapy, 2024 - Springer
Purpose Recent trials suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may
have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and …
have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and …
Interplay between myokine profile and glycemic control in type 2 diabetes mellitus patients with heart failure
AA Berezin, Z Obradovic, EV Novikov, E Boxhammer… - Diagnostics, 2022 - mdpi.com
Type 2 diabetes mellitus (T2DM) remains a powerful predictor of progressive heart failure
(HF), but it is not clear whether altered glycemic control interferes with HF progression via an …
(HF), but it is not clear whether altered glycemic control interferes with HF progression via an …
[PDF][PDF] Effects of water-sodium balance and regulation of electrolytes associated with antidiabetic drugs.
J Zhang, MN Li, GM Yang, XT Hou… - European Review for …, 2023 - europeanreview.org
As the prevalence of diabetes rises, the use of antidiabetic drugs becomes more frequent.
Thus, focusing on the effects of these drugs on water-sodium balance and electrolyte …
Thus, focusing on the effects of these drugs on water-sodium balance and electrolyte …
The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis
Aims Glucagon-like peptide 1 receptor agonists (GLP-1RA) decrease the risk of major
adverse cardiovascular events (MACE). However, their influence on the risk of heart failure …
adverse cardiovascular events (MACE). However, their influence on the risk of heart failure …
Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Y Huang, X Xu, J Liu, P Wang, X Wang, H Feng… - BMC Cardiovascular …, 2023 - Springer
Background In recent years, the incidence of diabetes mellitus has been increasing
annually, and cardiovascular complications secondary to diabetes mellitus have become the …
annually, and cardiovascular complications secondary to diabetes mellitus have become the …